^
Association details:
| Biomarker: | EPHA3 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
86P - The predictive values of EPHA3 mutations for response to immune checkpoint inhibitors in solid tumors
Published date:
09/13/2021
Excerpt:
...EPHA3 mutations were associated with prolonged OS in NSCLC, rather than other cancer types, suggesting that it might act as a predictive biomarker for ICIs therapy in NSCLC.
